Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Andreas M. Stark, Alexander Doukas, Heinz-Herrmann Hugo, Jürgen Hedderich, Kirsten Hattermann, H. Maximilian Mehdorn & Janka Held-Feindt. (2015) Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma. Neurological Research 37:2, pages 95-105.
Read now
Read now
Articles from other publishers (29)
Tian Gan, Yan Wang, Manyi Xie, Qiang Wang, Saisai Zhao, Peng Wang, Qinyu Shi, Xuanchen Qian, Faan Miao, Zhigang Shen & Er Nie. (2022) MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. Cancer Research 82:22, pages 4234-4246.
Crossref
Crossref
Kevin B. Elmore & Lauren R. Schaff. (2021) DNA Repair Mechanisms and Therapeutic Targets in Glioma. Current Oncology Reports 23:8.
Crossref
Crossref
Sheena Alphones, Uttara Chatterjee, Angad Singh, Anirban Das, Lateef Zameer, Rimpa Achari, Arpita Bhattacharya & Paromita Roy. (2021) Immunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas — institutional experience and review of literature. Child's Nervous System 37:8, pages 2521-2530.
Crossref
Crossref
Raúl Ortiz, Gloria Perazzoli, Laura Cabeza, Cristina Jiménez-Luna, Raquel Luque, Jose Prados & Consolación Melguizo. (2021) Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Current Neuropharmacology 19:4, pages 513-537.
Crossref
Crossref
Yi Wang, Nan Ji, Junmei Wang, Jingli Cao, Deling Li, Yang Zhang & Liwei Zhang. (2021) SCG3 Protein Expression in Glioma Associates With less Malignancy and Favorable Clinical Outcomes. Pathology and Oncology Research 27.
Crossref
Crossref
Ying ShiJian JiangYingzhe CuiYaodong ChenTianxiu DongHongda AnPengfei Liu. (2021)
MSH6
Aggravates the Hypoxic Microenvironment via Regulating HIF1A to Promote the Metastasis of Glioblastoma Multiforme
. DNA and Cell Biology 40:1, pages 93-100.
Crossref
Crossref
Sabrina Battista, Laura Cerchia & Monica Fedele. 2021. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies. Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies
365
400
.
Ghadeer Almuhaisen, Yazan Alhalaseh, Razan Mansour, Amer Abu-Shanab, Sura Al-Ghnimat & Maysa Al-Hussaini. (2020) Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA). Brain Tumor Pathology 38:1, pages 14-22.
Crossref
Crossref
Zoltan Kraboth & Bernadette Kalman. (2019) Longitudinal Characteristics of Glioblastoma in Genome-Wide Studies. Pathology & Oncology Research 26:4, pages 2035-2047.
Crossref
Crossref
Mario Caccese, Tamara Ius, Matteo Simonelli, Matteo Fassan, Daniela Cesselli, Angelo Dipasquale, Francesco Cavallin, Marta Padovan, Alessandro Salvalaggio, Marina Paola Gardiman, Miran Skrap, Vittorina Zagonel & Giuseppe Lombardi. (2020) Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study. International Journal of Molecular Sciences 21:18, pages 6716.
Crossref
Crossref
Danielle M. File, Katherine P. Morgan & Simon Khagi. (2020)
Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With
ATM
-Mutated Glioblastoma and
MSH6
-Deficient Lynch Syndrome
. JCO Precision Oncology:4, pages 841-847.
Crossref
Crossref
Cheng-Ta Hsieh & Da-Tong Ju. 2020. Tumor Progression and Metastasis. Tumor Progression and Metastasis.
Clémentine Bouchez, Emmanuelle Kempf & Christophe Tournigand. (2019) Traitement des autres tumeurs solides métastatiques MSI/dMMR. Bulletin du Cancer 106:2, pages 143-150.
Crossref
Crossref
Sabine Hombach-Klonisch, Maryam Mehrpour, Shahla Shojaei, Craig Harlos, Marshall Pitz, Ahmed Hamai, Krzysztof Siemianowicz, Wirginia Likus, Emilia Wiechec, Brian D. Toyota, Reyhane Hoshyar, Amir Seyfoori, Zahra Sepehri, Sudharsana R. Ande, Forough Khadem, Mohsen Akbari, Adrienne M. Gorman, Afshin Samali, Thomas Klonisch & Saeid Ghavami. (2018) Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. Pharmacology & Therapeutics 184, pages 13-41.
Crossref
Crossref
J. Stritzelberger, L. Distel, R. Buslei, R. Fietkau & F. Putz. (2017) Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine. Clinical and Translational Oncology 20:4, pages 508-516.
Crossref
Crossref
Gleyson Kleber do Amaral-Silva, Celeste Sánchez-Romero, Vivian Petersen Wagner, Manoela Domingues Martins, Hélder Antônio Rebelo Pontes, Eduardo Rodrigues Fregnani, Fernando Augusto Soares, Oslei Paes de Almeida, André Caroli Rocha, Alan Roger Santos-Silva, Felipe Paiva Fonseca & Pablo Agustin Vargas. (2017) Prognostic significance of hMSH2, hMSH3, and hMSH6 expression in ameloblastoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 124:3, pages 286-295.
Crossref
Crossref
Tiffany R. Hodges, Martina Ott, Joanne Xiu, Zoran Gatalica, Jeff Swensen, Shouhao Zhou, Jason T. Huse, John de Groot, Shulin Li, Willem W. Overwijk, David Spetzler & Amy B. Heimberger. (2017) Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology 19:8, pages 1047-1057.
Crossref
Crossref
Dong-dong Cheng, He-chun Lin, Shi-jie Li, Ming Yao, Qing-cheng Yang & Cun-yi Fan. (2017) CSE1L interaction with MSH6 promotes osteosarcoma progression and predicts poor patient survival. Scientific Reports 7:1.
Crossref
Crossref
Vani Santosh, Palavalasa Sravya & Arimappamagan Arivazhagan. 2017. Advances in Biology and Treatment of Glioblastoma. Advances in Biology and Treatment of Glioblastoma
19
55
.
B Campos, L R Olsen, T Urup & H S Poulsen. (2016) A comprehensive profile of recurrent glioblastoma. Oncogene 35:45, pages 5819-5825.
Crossref
Crossref
Chaoran Xie, Hansong Sheng, Nu Zhang, Shiting Li, Xiangyu Wei & Xuesheng Zheng. (2016) Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. Molecular and Clinical Oncology 5:2, pages 236-240.
Crossref
Crossref
Nicole Renee Parker, Peter Khong, Jonathon Fergus Parkinson, Viive Maarika Howell & Helen Ruth Wheeler. (2015) Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications. Frontiers in Oncology 5.
Crossref
Crossref
Gisela Natalia Castro, Niubys Cayado-Gutiérrez, Felipe Carlos Martín Zoppino, Mariel Andrea Fanelli, Fernando Darío Cuello-Carrión, Mayra Sottile, Silvina Beatriz Nadin & Daniel Ramón Ciocca. (2014) Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells. Cell Stress and Chaperones 20:2, pages 253-265.
Crossref
Crossref
Stephanie A. Nguyen, Owen D.M. Stechishin, H. Artee Luchman, Xueqing Q. Lun, Donna L. Senger, Stephen M. Robbins, J. Gregory Cairncross & Samuel Weiss. (2014)
Novel
MSH6
Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of
MGMT
Promoter Methylation
. Clinical Cancer Research 20:18, pages 4894-4903.
Crossref
Crossref
Klemen Zupancic, Andrej Blejec, Ana Herman, Matija Veber, Urska Verbovsek, Marjan Korsic, Miomir Knezevic, Primoz Rozman, Tamara Lah Turnsek, Kristina Gruden & Helena Motaln. (2014) Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach. Radiology and Oncology 48:3, pages 257-266.
Crossref
Crossref
Nancy H. Nabilsi, Loic P. Deleyrolle, Russell P. Darst, Alberto Riva, Brent A. Reynolds & Michael P. Kladde. (2014) Multiplex mapping of chromatin accessibility and DNA methylation within targeted single molecules identifies epigenetic heterogeneity in neural stem cells and glioblastoma. Genome Research 24:2, pages 329-339.
Crossref
Crossref
Prudence Donovan, Kathleen Cato, Roxane Legaie, Rumal Jayalath, Gemma Olsson, Bruce Hall, Sarah Olson, Samuel Boros, Brent A. Reynolds & Angus Harding. (2014) Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors. Mol. BioSyst. 10:4, pages 741-758.
Crossref
Crossref
Yoshinari Shinsato, Tatsuhiko Furukawa, Shunji Yunoue, Hajime Yonezawa, Kentarou Minami, Yukihiko Nishizawa, Ryuji Ikeda, Kohichi Kawahara, Masatatsu Yamamoto, Hirofumi Hirano, Hiroshi Tokimura & Kazunori Arita. (2013) Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget 4:12, pages 2261-2270.
Crossref
Crossref
Irene Rodríguez-Hernández, Juan Luis Garcia, Angel Santos-Briz, Aurelio Hernández-Laín, Jose María González-Valero, Juan Antonio Gómez-Moreta, Oscar Toldos-González, Juan Jesús Cruz, Javier Martin-Vallejo & Rogelio González-Sarmiento. (2013) Integrated Analysis of Mismatch Repair System in Malignant Astrocytomas. PLoS ONE 8:9, pages e76401.
Crossref
Crossref